Left Atrial Appendage Closure With the LAmbre

Completed

Phase N/A Results N/A

Trial Description

The study was to retrospectively analyse the efficacy and safety of LAA closure using the LAmbre in our center from April 2014 to November 2015.

Detailed Description

The study was to retrospectively analyse the efficacy and safety of percutaneous left atrial appendage (LAA) closure using the LAmbre (Lifetech Scientific Co., Ltd., Shenzhen, China) in our center from April 2014 to November 2015. 89.4% has finished the 12-month esophageal ecllocardiogrhy (TEE) examination. The average followup was 2-years.

Conditions

Interventions

  • LAA closure with LAmbre Device
    Intervention Desc: Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
    ARM 1: Kind: Experimental
    Label: LAA closure with LAmbre
    Description: The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.

Trial Population

The aim of this retrospective study was to evaluate the long-term follow-up results associated with left atrial appendage closure (LAAC) with the LAmbre (Lifetech Scientific Corp., Shenzhen, China) in patients with nonvalvular atrial fibrillation (NVAF).

Outcomes

Type Measure Time Frame Safety Issue
Primary Ischemic stroke up to 5 years
Secondary The composite safety and efficacy end-points up to 5 years
Secondary Successful sealing of the LAA up to 5 years

Sponsors